Starbucks' strategy shift will drive the stock even higher from where it trades now, according to TD Cowen. The research firm upgraded the coffee chain to buy from hold. It also hiked its price target on shares to $120 from $106, implying 13% upside from Wednesday's close. "Starbucks has numerous tangible drivers to deliver positive sales revisions in a strong category backdrop," analyst Andrew Ch...
Starbucks' strategy shift will drive the stock even higher from where it trades now, according to TD Cowen. The research firm upgraded the coffee chain to buy from hold. It also hiked its price target on shares to $120 from $106, implying 13% upside from Wednesday's close. "Starbucks has numerous tangible drivers to deliver positive sales revisions in a strong category backdrop," analyst Andrew Charles said Thursday in a note to clients. "As the company prioritizes labor investments, we forecast margins will recover amid our combined expectations for sales leverage, easing COGS & incentivized non-core cost cuts." TD Cowen expects Starbucks to notch a 4% increase in its same-store sales in fiscal year 2028. Its forecast comes in above the Street's consensus estimate of 3.4%, according to the analyst note. Starbucks remains in the "early innings" of a push to revitalize its operations in North America, Charles said. The cafe operator saw its sales slump for nearly two years, beginning around 2023. However, it began reversing the decline late last year. Starbucks' turnaround follows the implementation of its "Back to Starbucks" plan — a strategy to overhaul the firm's marketing, menu innovation and customer loyalty programs to boost its bottom line and stock. The plan has so far shown signs of success, with shares rising 26% year to date. If that gain holds, it would mark Starbucks' first annual gain since 2021. TD Cowen's call goes against consensus on Wall Street. Of the 40 analysts covering Starbucks, just 18 have a buy or strong buy rating on the stock, while 20 have a hold on it, LSEG data shows.
From James Bond’s breakfasts to the kimchi fried rice in Crying in H Mart, a book’s food can often linger longer in our memories than its characters or storylines Sign up here for our weekly food newsletter, Feast When I first had the idea for my debut novel, The Underdog , which came out last week, I knew it had to include food. After all, the received wisdom is to write about what you know and, ...
From James Bond’s breakfasts to the kimchi fried rice in Crying in H Mart, a book’s food can often linger longer in our memories than its characters or storylines Sign up here for our weekly food newsletter, Feast When I first had the idea for my debut novel, The Underdog , which came out last week, I knew it had to include food. After all, the received wisdom is to write about what you know and, after almost two decades’ worth of recipes, features and restaurant reviews, it’s surely my specialist subject. Though a grumpy terrier threatens to steal the limelight, the book’s (ostensible) main character, Katy, is a newly qualified pastry chef who goes from turning out heritage duck egg and black garlic mayo sourdough sandwiches in a painfully pretentious London cafe, to making cheese scones with foraged sea buckthorn jam on the west coast of Scotland. Her journey also involves a Michelin-starred restaurant and a bespoke baking business (as well as a couple of disastrous run-ins with bitchy critics, including on a television gameshow involving Sue Perkins and a chocolate souffle challenge). I had an absolute blast writing the book, and the food sections were definitely the most fun – thinking about what a starred restaurant might serve with a salted chocolate tart, say ( Fergus Henderson’s recipe is here , but I’m pretty sure he wouldn’t pair it with a beetroot sorbet and walnut crumb), or what a critic might order for lunch at Margot Henderson’s Rochelle Canteen ( bitter greens , like our own Rachel Roddy’s, for a start). In fact, from the glistening, bronzed hunk of pork with salsa verde and pressed potatoes set in front of the UK’s most feared culinary taste-maker, to the merguez and chip baguette Katy eats on the pavement after kidnapping a dog she doesn’t even like, the food is the real star. Continue reading...
Sundry Photography HP Enterprise ( HPE ) disclosed on Thursday that it has completed the sale of a 13.8% stake in IT solutions company H3C Technologies for $986.8M to several Chinese entities, including Unisplendour International Technology Limited, also known as UNIS. The sale was first disclosed on Dec. 1, 2025. HPE also said that it expects to sell the remaining 5.2% of H3C held by some of its ...
Sundry Photography HP Enterprise ( HPE ) disclosed on Thursday that it has completed the sale of a 13.8% stake in IT solutions company H3C Technologies for $986.8M to several Chinese entities, including Unisplendour International Technology Limited, also known as UNIS. The sale was first disclosed on Dec. 1, 2025. HPE also said that it expects to sell the remaining 5.2% of H3C held by some of its subsidiaries to UNIS for approximately $370.4M, according to the previously disclosed announcement. HPE shares rose 3.2% in premarket trading after it was reported that additional activist investors took a stake in the IT giant. More on Hewlett Packard Enterprise Hewlett Packard Enterprise: Network Segment Boosted By Juniper Acquisition Hewlett Packard Enterprise: AI Drives The Dominant Growth Theme, As Buy Rating Reaffirmed Hewlett Packard Enterprise: Too Much Demand Isn't A Bad Problem Hewlett Packard Enterprise gains on report of additional activist investors Dell, HP Enterprise in focus as BofA ups price targets on agentic AI boost
“先合作、后市场”的策略可以让中国机器人企业积累海外本地化的适配经验。 “中国科技公司发展得很快，机器人技术迭代迅速。”在GReAT2026全球智能康复与机器人技术峰会上，来自美国的José Luis Pons这样评价中国企业在全球康复领域中的表现。 José是 Shirley Ryan AbilityLab（前身芝加哥康复中心）下肢机器人技术研究所的科研主席。这所机构与中国AI机器人企业傅利叶合...
“先合作、后市场”的策略可以让中国机器人企业积累海外本地化的适配经验。 “中国科技公司发展得很快，机器人技术迭代迅速。”在GReAT2026全球智能康复与机器人技术峰会上，来自美国的José Luis Pons这样评价中国企业在全球康复领域中的表现。 José是 Shirley Ryan AbilityLab（前身芝加哥康复中心）下肢机器人技术研究所的科研主席。这所机构与中国AI机器人企业傅利叶合作已经近7年。今年，约有70家海外合作伙伴参加该峰会。 据产业研究相关机构报告，中国成为全球最大的康复机器人出口国之一，东南亚等新兴市场增长明显。这一细分赛道出海逐渐从单品出海向技术应用解决方案与产业体系出海转变，中国康复机器人也正在凭借新兴技术优势角逐海外市场。 AI技术成为康复设备市场新趋势 Global Market Insights发布报告显示，全球康复设备市场规模在2025年估计为230亿美元，该市场预计将从2026年的246亿美元增长至2035年的472亿美元。其中，最大的市场为北美地区，增长最快地区则是亚太。 推动市场增长的因素包括肌肉骨骼疾病发病率上升、老龄化人口增长与慢性疾病患病率上升等等。目前，机器人康复技术主要用于脑卒中治疗和神经康复。 此次峰会现场，康复设备与脑机接口、AI等技术的结合应用受到多位海外客户关注。 José介绍，AI、具身智能新兴技术是康复市场中的最新应用趋势，行业正在利用新技术从患者身上获取更多的数据，从而实现干预措施个性化，比如借助传感器、脑机接口等技术。他还认为，AI带来的颠覆性变革，在于能够将机器人系统变得更加智能，成为与人类专家协同合作的技术伙伴。 苏黎世联邦理工学院运动与感官系统实验室主导人Robert Riener也讲述了自己的观察。他介绍，可以利用AI预防多种症状和疾病，比如监测患者的生理数据、社交行为以及睡眠觉醒节律，并利用这些数据来预测某些症状、疾病，或是他们的康复进程。 名古屋大学大学院医学系研究科特聘教授Shingo Shimoda也在分享中介绍，游戏化已成为康复机器人领域提升患者参与度与训练量的有效策略。他提出了一种基于生物信号驱动的训练范式，将训练重点从“游戏结果”转向“可解释的神经肌肉反馈”，使原本隐性的运动控制过程能够被患者与治疗师实时感知和理解。 大会现场展示了脑机接口与下肢外骨骼机器人的结合应用。一位...
Bullish ( BLSH ) stock dropped 8.3% in Thursday premarket trading after Q1 earnings and revenue fell short of Wall Street consensus estimates as its operating expenses rose. The company also highlighted its upcoming $4.2B acquisition of Equiniti, which will unify a regulated transfer agent with end-to-end tokenization infrastructure. The investing platform reaffirmed its 2026 guidance for subscrip...
Bullish ( BLSH ) stock dropped 8.3% in Thursday premarket trading after Q1 earnings and revenue fell short of Wall Street consensus estimates as its operating expenses rose. The company also highlighted its upcoming $4.2B acquisition of Equiniti, which will unify a regulated transfer agent with end-to-end tokenization infrastructure. The investing platform reaffirmed its 2026 guidance for subscription, services & other revenue (non-IFRS) of $220.0M-$250.0M, adjusted operating expenses (non-IFRS) of $210.0M-$230.0M, and finance expense of $52.0M-$60.0M. Combined with Equiniti, the company projects 2026 combined revenue of ~$1.3B, adjusted EBITDA less capex of ~$500M, and adjusted net income of ~$280M. On the bottom line, its loss per share continued to widen. Q1 GAAP EPS of -$3.85, vs. the average analyst estimate of -$2.23, compared with -$3.73 in Q4 2025 and -$3.04 in last year’s Q1. Q1 adjusted net income of $20.3M, vs. the Visible Alpha consensus of $24.5M, decreased from $28.9M in the previous quarter and jumped from $2.1M in the year-ago quarter. Adjusted revenue of $92.8M, trailing the $94.2M consensus, increased from $92.5M in Q4 and $62.4M in Q1 2025. Bullish’s ( BLSH ) total trading volume was $197B, exceeding the $188.5B Visible Alpha estimate and falling from $222B in the prior quarter. The Q1 2026 total included $176B in spot trading and $12B in options trading. Adjusted transaction revenue of $38M, topping the $36M Visible Alpha estimate, was flat with Q4 and declined from $42M in last year’s Q1. Adjusted operating expenses of $57.7M, higher than the Visible Alpha consensus of $56.3M, increased from $48.1M in the previous quarter and $49.2M a year ago. Adjusted EBITDA dropped to $35.1M from $44.5M in Q4 and surged from $13.2M in Q1 2025. The latest quarter missed the $38.5M Visible Alpha consensus. Digital asset balances as of March 31, 2026, totaled $2.97B, including $1.58B of bitcoin ( BTC-USD ) and $30M of ethereum ( ETH-USD ). Since the end of the q...
travellinglight/iStock via Getty Images Biogen ( BIIB ) added ~9% in the premarket on Thursday after the company shared results from a mid-stage trial evaluating diranersen, an experimental therapy for Alzheimer’s disease developed in collaboration with Ionis Pharmaceuticals ( IONS ). Citing topline data from its Phase 2 CELIA study, the company said that diranersen, an antisense oligonucleotide d...
travellinglight/iStock via Getty Images Biogen ( BIIB ) added ~9% in the premarket on Thursday after the company shared results from a mid-stage trial evaluating diranersen, an experimental therapy for Alzheimer’s disease developed in collaboration with Ionis Pharmaceuticals ( IONS ). Citing topline data from its Phase 2 CELIA study, the company said that diranersen, an antisense oligonucleotide designed to target a protein called "tau," slowed clinical decline across all studied doses in patients with early Alzheimer’s disease. Additionally, in line with early-stage trial data, all studied doses of the drug were associated with significant reductions of tau pathology, which is believed to cause neurodegeneration and cognitive decline in Alzheimer's. “The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact and cognitive benefit in early Alzheimer’s disease,” Biogen ( BIIB ) said. However, the 416-patient trial, in which patients received diranersen intrathecally, failed to reach its primary endpoint that assessed the dose-response for the 76-week change in the Clinical Dementia Rating–Sum of Boxes. The safety and tolerability profile of the drug was consistent with data from a Phase 1b trial and its established safety profile. “We are excited by these Phase 2 data, which give us the confidence to advance diranersen to registrational development,” said Priya Singhal, Biogen’s ( BIIB ) head of development. More on Biogen, Ionis Pharmaceuticals Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript Ionis Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation Biogen says FDA extends review of Leqembi alzheimer’s injection Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B
For every standing ovation there’s a riotous backlash – the film festival’s history is littered with boos, protests, furious rows and career-defining disasters Part of the appeal of Cannes is its sense of old-school glamour. It is, however, a shame that the glamour often comes at the expense of logic and practicality. In 2015, a group of women were barred from the gala screening of Todd Haynes’ hi...
For every standing ovation there’s a riotous backlash – the film festival’s history is littered with boos, protests, furious rows and career-defining disasters Part of the appeal of Cannes is its sense of old-school glamour. It is, however, a shame that the glamour often comes at the expense of logic and practicality. In 2015, a group of women were barred from the gala screening of Todd Haynes’ historical lesbian romance Carol for not adhering to the rule that women must wear high heels. The same happened to producer Valeria Richter, even though part of her left foot had been amputated. A year later, Julia Roberts made her displeasure about this known by walking the red carpet barefoot. Continue reading...
Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and adaptability to evolving market demands.
Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and adaptability to evolving market demands.
The competition regulator has launched an investigation into Microsoft over software used by hundreds of thousands of UK businesses and public sector organisations. The CMA will assess where bundling of Microsoft products limits in interoperability, the ability of computer systems to work together and exchange information, and if default settings prevent users from switching to alternatives. It ha...
The competition regulator has launched an investigation into Microsoft over software used by hundreds of thousands of UK businesses and public sector organisations. The CMA will assess where bundling of Microsoft products limits in interoperability, the ability of computer systems to work together and exchange information, and if default settings prevent users from switching to alternatives. It had heard that UK customers may not always be able to effectively combine software from Microsoft with other providers, limiting their access to the best products at the lowest prices.
Genie Energy press release ( GNE ): Q1 GAAP EPS of $0.11 misses by $0.07 . Revenue of $142.3M (+4.0% Y/Y) beats by $18.47M . Lowering full year 2026 guidance from $40 to $50 million, to $32.5 to $40 million in Adjusted EBITDA. Shares -1.5% PM. More on Genie Energy Small-Cap rutility stocks ranked by quant ratings after earnings season Seeking Alpha’s Quant Rating on Genie Energy Historical earning...
Genie Energy press release ( GNE ): Q1 GAAP EPS of $0.11 misses by $0.07 . Revenue of $142.3M (+4.0% Y/Y) beats by $18.47M . Lowering full year 2026 guidance from $40 to $50 million, to $32.5 to $40 million in Adjusted EBITDA. Shares -1.5% PM. More on Genie Energy Small-Cap rutility stocks ranked by quant ratings after earnings season Seeking Alpha’s Quant Rating on Genie Energy Historical earnings data for Genie Energy Dividend scorecard for Genie Energy Financial information for Genie Energy
M. Suhail/iStock Editorial via Getty Images TD Cowen upgraded Starbucks ( SBUX ) to a Buy rating on Thursday after having the coffee chain stock set at Hold. Analyst Andrew Charles said Starbucks ( SBUX ) has numerous tangible drivers to deliver positive sales revisions in a strong category backdrop. Amid ongoing labor investments, Charles and his team forecast margins will still recover for Starb...
M. Suhail/iStock Editorial via Getty Images TD Cowen upgraded Starbucks ( SBUX ) to a Buy rating on Thursday after having the coffee chain stock set at Hold. Analyst Andrew Charles said Starbucks ( SBUX ) has numerous tangible drivers to deliver positive sales revisions in a strong category backdrop. Amid ongoing labor investments, Charles and his team forecast margins will still recover for Starbucks ( SBUX ) due to expectations for sales leverage, easing COGS, and incentivized non-core cost cuts. The firm is confident that Starbucks ( SBUX ) management can deliver sales and EPS upside to justify its earnings estimate. "Under CEO Brian Niccol, we believe the company has identified and sequenced a durable, multifaceted brand revitalization plan that is in early innings," highlighted Charles. "This is centered on operations, marketing, beverage innovation, and loyalty/digital," he added. The expectation is that positive sales revisions, along with easing commodity costs and management incentives to achieve at least $800M of cost cuts by the end of 2027, will allow the model to close in on $4.00 of EPS in 2028. TD Cowen boosted its price target on SBUX to $120. Shares of Starbucks ( SBUX ) were up 1.3% in premarket trading to $107.28. The coffee chain stock carved out a new 52-week high of $108.05 on Wednesday. More on Starbucks Starbucks: The Comeback Has Started But The Growth Story Is Not Proven Starbucks Earnings: Fully Caffeinated? Starbucks: This Undefeatable Coffee Champion Has Been Judged Beyond Logic Earnings Scorecard: 12 out of 15 S&P 500 consumer discretionary firms beat EPS estimates this week Earnings Scoreboard: 82% of S&P 500 reporting firms top EPS estimates as 78% of firms post Y/Y earnings growth